Novartis Ag (NVS) Growth Rates Comparisons to Major Pharmaceutical Preparations Industry, Sector, Market. Sales, Income, EPS
CSIMarket Company Name, Ticker, Suppliers, else..
 
Novartis Ag  (NYSE: NVS)
 

Novartis Ag Growth Comparisons

Select each growth Category to receive further Information




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NVS Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q4 MRQ) 9.57 % 12.12 % 7.69 % 5.68 %
Q / Q Revenue Growth (Q4 MRQ) - 3.94 % 3.27 % 2.63 %
Y / Y Revenue Growth (for 12 months ending Q4 TTM) 10.11 % 7.48 % 5.74 % %
Sequential Revenue Growth (for 12 months ending Q4 TTM) - 4.08 % 2.39 % 1.74 %
Revenue 5 Year Average Growth 2.58 % 14.14 % 10.99 % 7.73 %


NVS's Growth Comparisons in IV. Quarter 2025




Novartis Ag's 9.57% year on year Revenue increase in the fourth quarter 2025 to 56.67 billions, marks slow-down from Novartis Ag's growth trends, and competes unfavorably to the 12.12% rise in the Major Pharmaceutical Preparations industry, but beating the 7.69% growth in the Healthcare sector. Above the average sales gains in the Healthcare and in the Major Pharmaceutical Preparations industry as well, helped to elevate overall market growth to 5.68%.

Sequentially company's Revenue were unchanged from the third quarter results. . Looking into annual growth, sales grew by 2.58% on average in last five years, while S & P 500's including only Businesses with the fourth quarter 2025 earnings reports, average yearly sales growth is 7.73%.

NVS Growth Rates by Company's Segments

Segment Name
Y / Y
Sequential
Switzerland
-
-
US
-
-
China
-
-
Germany
-
-
Other
-
-
Change to prior year-end
-
-
US Change to prior year-end
-
-
Europe
-
-
Europe Change to prior year-end
-
-
Asia Africa Australasia
-
-
Asia Africa Australasia Change to prior year-end
-
-
Canada and Latin America
-
-
Canada and Latin America Change to prior year-end
-
-
Established Markets
-
-
Established Markets Change to prior year-end
-
-
Emerging Growth Markets
-
-
Emerging Growth Markets Change to prior year-end
-
-
Rest of the world
-
-
Top 20 products
-
-
Cardiovascular renal and metabolic
-
-
Cardiovascular renal and metabolic Entresto
-
-
Cardiovascular renal and metabolic Leqvio
-
-
Cardiovascular renal and metabolic Vanrafia
-
-
Cardiovascular renal and metabolic Top 20 products Entresto
-
-
Cardiovascular renal and metabolic Top 20 products Leqvio
-
-
Immunology
-
-
Immunology Cosentyx
-
-
Immunology Ilaris
-
-
Immunology Xolair
-
-
Immunology Rhapsido
-
-
Immunology Top 20 products Cosentyx
-
-
Immunology Top 20 products Ilaris
-
-
Immunology Top 20 products Xolair
-
-
Neuroscience
-
-
Neuroscience Kesimpta
-
-
Neuroscience Zolgensma
-
-
Neuroscience Aimovig
-
-
Neuroscience Top 20 products Kesimpta
-
-
Neuroscience Top 20 products Zolgensma
-
-
Oncology
-
-
Oncology Kisqali
-
-
Oncology Tafinlar Mekinist
-
-
Oncology Jakavi
-
-
Oncology Pluvicto
-
-
Oncology Promacta Revolade
-
-
Oncology Scemblix
-
-
Oncology Tasigna
-
-
Oncology Lutathera
-
-
Oncology Fabhalta
-
-
Oncology Piqray Vijoice
-
-
Oncology Top 20 products Kisqali
-
-
Oncology Top 20 products Tafinlar Mekinist
-
-
Oncology Top 20 products Jakavi
-
-
Oncology Top 20 products Pluvicto
-
-
Oncology Top 20 products Promacta Revolade
-
-
Oncology Top 20 products Scemblix
-
-
Oncology Top 20 products Tasigna
-
-
Oncology Top 20 products Lutathera
-
-
Oncology Top 20 products Fabhalta
-
-
Established Brands Sandostatin Group
-
-
Established Brands Exforge Group
-
-
Established Brands Lucentis
-
-
Established Brands Diovan Group
-
-
Established Brands Galvus Group
-
-
Established Brands Kymriah
-
-
Established Brands Contract manufacturing
-
-
Established Brands Other
-
-
Established Brands Top 20 products Sandostatin Group
-
-
Established Brands Top 20 products Exforge Group
-
-
Established Brands Top 20 products Lucentis
-
-
Established Brands Top 20 products Diovan Group
-
-
Established Brands Established Brands
-
-
US Top 20 products
-
-
US Cardiovascular renal and metabolic Top 20 products Entresto
-
-
US Cardiovascular renal and metabolic Top 20 products Leqvio
-
-
US Immunology Top 20 products Cosentyx
-
-
US Immunology Top 20 products Ilaris
-
-
US Neuroscience Top 20 products Kesimpta
-
-
US Neuroscience Top 20 products Zolgensma
-
-
US Oncology Top 20 products Kisqali
-
-
US Oncology Top 20 products Tafinlar Mekinist
-
-
US Oncology Top 20 products Pluvicto
-
-
US Oncology Top 20 products Promacta Revolade
-
-
US Oncology Top 20 products Scemblix
-
-
US Oncology Top 20 products Tasigna
-
-
US Oncology Top 20 products Lutathera
-
-
US Oncology Top 20 products Fabhalta
-
-
US Established Brands Top 20 products Sandostatin Group
-
-
US Established Brands Top 20 products Exforge Group
-
-
US Established Brands Top 20 products Diovan Group
-
-
Rest of the world Top 20 products
-
-
Rest of the world Cardiovascular renal and metabolic Top 20 products Entresto
-
-
Rest of the world Cardiovascular renal and metabolic Top 20 products Leqvio
-
-
Rest of the world Immunology Top 20 products Cosentyx
-
-
Rest of the world Immunology Top 20 products Ilaris
-
-
Rest of the world Immunology Top 20 products Xolair
-
-
Rest of the world Neuroscience Top 20 products Kesimpta
-
-
Rest of the world Neuroscience Top 20 products Zolgensma
-
-
Rest of the world Oncology Top 20 products Kisqali
-
-
Rest of the world Oncology Top 20 products Tafinlar Mekinist
-
-
Rest of the world Oncology Top 20 products Jakavi
-
-
Rest of the world Oncology Top 20 products Pluvicto
-
-
Rest of the world Oncology Top 20 products Promacta Revolade
-
-
Rest of the world Oncology Top 20 products Scemblix
-
-
Rest of the world Oncology Top 20 products Tasigna
-
-
Rest of the world Oncology Top 20 products Lutathera
-
-
Rest of the world Oncology Top 20 products Fabhalta
-
-
Rest of the world Established Brands Top 20 products Sandostatin Group
-
-
Rest of the world Established Brands Top 20 products Exforge Group
-
-
Rest of the world Established Brands Top 20 products Lucentis
-
-
Rest of the world Established Brands Top 20 products Diovan Group
-
-
Rest of portfolio
-
-
US Rest of portfolio
-
-
Rest of the world Rest of portfolio
-
-
Total
-
-


Growth Rates of NVS's Income in the fourth quarter 2025


NVS Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q4 MRQ) 21.31 % 155.5 % 43.36 % -0.27 %
Sequential Operating Income Change (Q4 MRQ) - -35.64 % -22.05 % -8.98 %
Y / Y Operating Income Growth (Q4 TTM) 21.28 % 18.81 % 19.61 % 9.24 %
Sequential Operating Income Growth (Q4 TTM) 15.97 % 15.12 % 7.78 % -0.22 %
Operating Income 5 Year Avg. Change 11.69 % 0.11 % -0.96 % 9 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q4 MRQ) 16.99 % - -97.24 % 22.99 %
Sequential Income from Cont. Ops. Change (Q4 MRQ) - - -95.98 % 8.13 %
Y / Y Income from Cont. Ops. Change (Q4 TTM) 16.99 % 3.72 % 9.35 % 11.58 %
Sequential Income from Cont. Ops. Change (Q4 TTM) 16.99 % -3.53 % -5.92 % 4.61 %
Income from Cont. Ops. 5 Year Avg. Change 11.59 % -18.69 % -17.93 % 8.34 %

NVS Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q4 MRQ) 16.99 % 128.53 % 37.76 % 25.85 %
Q / Q Net Income Growth (Q4 MRQ) - 19.99 % -20.76 % 7.59 %
Y / Y Net Income Change (Q4 TTM) 18.48 % -18.88 % -9.02 % 9.66 %
Sequential Net Income Change (Q4 TTM) 12.7 % -3.09 % -6.02 % 5.18 %
Net Income 5 Year Avg. Growth 11.59 % 14.51 % 6.2 % 9.47 %

NVS's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q4 MRQ) - - -97.24 % 22.99 %
Sequential EPS from Cont. Ops. Change (Q4 MRQ) - - -95.98 % 8.13 %
Y / Y EPS from Cont. Ops. Change (Q4 TTM) 29.92 % - - -
Sequential EPS from Cont. Ops. Change (Q4 TTM) 0 % - - 33 %
EPS from Cont. Ops. 5 Year Avg. Growth 15.26 % -29.47 % -17.93 % 8.34 %



NVS EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q4 MRQ) - 90.85 % 37.76 % 8.34 %
Q / Q EPS Net Growth (Q4 MRQ) - 30.6 % -20.76 % 7.59 %
Y / Y EPS Net Change (for 12 months ending Q4 TTM) - - - 92.65 %
Sequential EPS Net Change (for 12 months ending Q4 TTM) 0 % - - 33 %
EPS Net 5 Year Avg. Change 15.26 % 14.51 % 6.2 % 9.47 %



Novartis Ag reported bottom-line of $ 0.00 in the fourth quarter, compare to $ 0.00 in the same quarter a year ago. Major Pharmaceutical Preparations industry grew by 90.85%, while Healthcare sector increased by 37.76%, and overall market improved by 25.85%.

Sequentially company's EPS were unchanged from the third quarter results. . Looking into annual growth, income per share grew by 15.26% on average in the last five years, while the S & P 500's including only the businesses with the fourth quarter 2025 financial results, average yearly income per share growth is 9.47%.

NVS Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q4 MRQ) 8.26 % 56.99 % 49.29 % 32.85 %
Sequential Free Cash Flow Change (Q4 MRQ) - -24.26 % -6.05 % 113.08 %
Y / Y Free Cash Flow Change (Q4 TTM) 7.63 % 96.5 % 72.27 % 10.44 %
Sequential Free Cash Flow Change (Q4 TTM) 8.61 % 80.96 % 57.27 % 9.43 %
Free Cash Flow 5 Year Avg. Change 6.64 % 9.45 % 6.34 % 10.76 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q4 MRQ) - -82.47 % - -81.15 %
Sequential Net Cash Flow Change (Q4 MRQ) - - - -
Y / Y Net Cash Flow Change (Q4 TTM) - 198.68 % 173.42 % -
Sequential Net Cash Flow Change (Q4 TTM) - 15908 % - -
Net Cash Flow 5 Year Avg. Change 0.62 % -8.21 % -1.7 % -32.35 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q4 MRQ) 13.32 % 3.32 % 11.12 % 22.34 %
Sequential Capital Expenditures Change (Q4 MRQ) 367.67 % 26.08 % 20.75 % 17.09 %
Y / Y Capital Expenditures Change (Q4 TTM) 17.18 % 24.06 % 16.17 % 41.57 %
Sequential Capital Expenditures Change (Q4 TTM) 8.97 % 20.81 % 14.03 % 6.83 %
Capital Expenditures 5 Year Avg. Change 3.96 % 10.81 % 9 % 10.74 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Y/Y Annual




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.